PAI
TGTX icon

Pittenger & Anderson Inc’s TG Therapeutics TGTX Stock Holding History

Pittenger & Anderson Inc’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.3K Hold
612
– – ﹤0.01% 363
2025
Q4 		$18.2K Hold
612
– – ﹤0.01% 371
2025
Q3 		$22.1K Buy
+612
New +$20.2K ﹤0.01% 338

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pittenger & Anderson Inc's TGTX Position: Q1 2026 in Review

Pittenger & Anderson Inc held its TG Therapeutics (TGTX) position steady in Q1 2026 at 612 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

Pittenger & Anderson Inc first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $22.1K in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Pittenger & Anderson Inc held 612 shares of TG Therapeutics worth $20.3K as of Q1 2026.
  • Pittenger & Anderson Inc left its TG Therapeutics share count unchanged in Q1 2026.
  • TG Therapeutics made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q1 2026, its #363 holding.
  • Pittenger & Anderson Inc first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Pittenger & Anderson Inc's TG Therapeutics position peaked at $22.1K in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2026, filed 1 May 2026.